Astel­las buys in­to Fre­quen­cy's re­gen­er­a­tive med strat­e­gy with a $625M al­liance on hear­ing loss

The ex­ec­u­tive team at Fre­quen­cy Ther­a­peu­tics nev­er over­sold the re­sults of their maid­en Phase I/II study for a new drug to rec­ti­fy hear­ing loss. It was, they said back in April, pri­mar­i­ly about safe­ty and tol­er­a­bil­i­ty, where their drug FX-322 per­formed as they had hoped. 

That ear­ly glimpse of ef­fi­ca­cy every­one search­es for in their first try on hu­mans? 

(I)mprove­ments in hear­ing func­tion, in­clud­ing au­diom­e­try and word scores, were ob­served in mul­ti­ple FX-322 treat­ed pa­tients.

We don’t know ex­act­ly what that means. But what­ev­er the de­tails, Astel­las found enough in the da­ta to jump in with a siz­able col­lab­o­ra­tion deal.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER